Triple-negative breast cancer: Neoadjuvant durvalumab improves prognosis

被引：0
|
作者：
Kunzell, Judith Lorenz
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 02期
关键词：
D O I：
10.1055/a-1985-2104
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Eine vielversprechende Therapiestrategie beim fruhen Mammakarzinom ist die Gabe von Immuncheckpoint-Inhibitoren zusatzlich zur neoadjuvanten Chemotherapie. Die GeparNuevo-Studie prufte bei Frauen mit einem triple-negativen Tumor den PD-L1-(Programmed Death-Ligand 1-)Inhibitor Durvalumab zusatzlich zur anthrazyklin-/taxanbasierten Zytostase gegen Placebo. Nun liegen die Ergebnisse zu den sekundaren uberlebensendpunkten vor.
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pathologic method for extracting good prognosis group in triple-negative breast cancer after neoadjuvant chemotherapy
    Eguchi, Yuki
    Nakai, Tokiko
    Kojima, Motohiro
    Wakabayashi, Masashi
    Sakamoto, Naoya
    Sakashita, Shingo
    Miyazaki, Saori
    Taki, Tetsuro
    Watanabe, Reiko
    Watanuki, Rurina
    Yamauchi, Chisako
    Iwatani, Tsuguo
    Mukohara, Toru
    Onishi, Tatsuya
    Ishii, Genichiro
    CANCER SCIENCE, 2022, 113 (04) : 1507 - 1518
  • [42] Comparison of the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy for improving prognosis in triple-negative breast cancer patients
    Li, Wangbin
    Chang, Yuwei
    Bai, Xiaohui
    Cao, Hongxin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (08): : 3978 - 3989
  • [43] Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
    Bae, Soo Youn
    Lee, Jeong Hyeon
    Bae, Jeoung Won
    Jung, Seung Pil
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) : 291 - 298
  • [44] Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer
    Lou, Caiyu
    Jin, Fenyuan
    Zhao, Qiang
    Qi, Hongming
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (05): : 3240 - 3246
  • [45] Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer
    Wang, Cheng
    Shi, Qiyun
    Zhang, Guozhi
    Yan, Wenting
    Wu, Xiujuan
    Wan, Andi
    Xiong, Siyi
    Yuan, Long
    Tian, Hao
    Ma, Dandan
    Jiang, Jun
    Zhang, Yi
    Qi, Xiaowei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Analysis of the Clinicopathologic Features and Prognosis in Triple-Negative Breast Cancer
    Dehong Yang1 Hong Liu2 Jing Zhao21 Department of Surgery
    Chinese Journal of Clinical Oncology, 2008, (05) : 387 - 390
  • [47] Prognosis of Patients with Triple-negative Breast Cancer and Brain Metastasis
    Venkitaraman, R.
    Joseph, T.
    Dhadda, A.
    Chaturvedi, A.
    Upadhyay, S.
    CLINICAL ONCOLOGY, 2009, 21 (09) : 729 - 730
  • [48] Update on triple-negative breast cancer: prognosis and management strategies
    Brouckaert, Olivier
    Wildiers, Hans
    Floris, Giuseppe
    Neven, Patrick
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2012, 4 : 511 - 520
  • [49] Extent of Breast Surgery After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
    Ponzone, Riccardo
    Montemurro, Filippo
    JAMA SURGERY, 2020, 155 (08) : 785 - 786
  • [50] The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
    Johnson, Kai Conrad Cecil
    Goldstein, Daniel
    Tharakan, Jasmin
    Quiroga, Dionisia
    Kassem, Mahmoud
    Grimm, Michael
    Miah, Abdul
    Vargo, Craig
    Berger, Michael
    Sudheendra, Preeti
    Pariser, Ashley
    Gatti-Mays, Margaret E. E.
    Williams, Nicole
    Stover, Daniel
    Sardesai, Sagar
    Wesolowski, Robert
    Ramaswamy, Bhuvaneswari
    Tozbikian, Gary
    Schnell, Patrick M. M.
    Cherian, Mathew A. A.
    ONCOLOGY AND THERAPY, 2023, 11 (03) : 361 - 374
12345